Article
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology (Baltimore, Md.) - 1 Jun 2013
Sulkowski Mark S, Bourlière Marc, Bronowicki Jean-Pierre, Asselah Tarik, Pawlotsky Jean-Michel, Shafran Stephen D, Pol Stanislas, Mauss Stefan, Larrey Dominique, Datsenko Yakov, Stern Jerry O, Kukolj George, Scherer Joseph, Nehmiz Gerhard, Steinmann Gerhard G, Böcher Wulf O
Abstract excerpt
UNLABELLED: Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor. In all, 290 noncirrhotic HCV genotype (GT)-1 patients with prior null (<1 log10 viral load [VL] drop at any time on treatment) or partial response (≥1 log10 VL drop but never undetectable on treatment) were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in combination with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.